Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00280-017-3245-5 http://scihub22266oqcxt.onion/10.1007/s00280-017-3245-5 C5893148!5893148 !28280971     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28280971 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Cancer+Chemother+Pharmacol 2017 ; 79 (4 ): 673-680 Nephropedia Template TP {{tp|p=28280971 |t=2017. A phase 1 study of anti-TGF? receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors |pdf=|usr=}}{{28280971 }} gab.com Text A phase 1 study of anti-TGF receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors JO: Cancer Chemother Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=28280971 #FOAvip PURPOSE: LY3022859 is an anti-TGF?RII IgG(1) monoclonal antibody that inhibits receptor-mediated signaling activation. The primary objective of this phase I study was to determine a phase II dose in patients with advanced solid tumors. Secondary objectives were to assess safety and pharmacokinetics (PK). METHODS: LY3022859 was infused intravenously (IV) at 1.25 mg/kg over 1 h every 2 weeks (Q2W) (cohort 1A) and at flat doses of 12.5 mg (cohort 1B) and 25 mg (cohort 2) over 3 h Q2W. RESULTS: Fourteen patients were enrolled in cohorts 1A (n = 2), 1B (n = 5), and 2 (n = 7). DLTs were experienced by both patients in cohort 1A (infusion-related reaction) and 2 patients in cohort 2 (cytokine release syndrome and infusion-related reaction). No MTD was determined. At the 25 mg dose level (cohort 2), after fifth infusion, LY3022859 had a short t(1/2) (4.37-7.80 h) and rapid clearance (CL(ss), 0.412 L/h). Exposure increased twofold (from 28.5 to 60.2 ?g·h/mL) with increase in dose from 12.5 to 25 mg. No accumulation was observed after repeat administration. CONCLUSIONS: The MTD for LY3022859 was not determined. Dose escalation beyond 25 mg was considered unsafe due to worsening symptoms (uncontrolled cytokine release) despite prophylaxis (corticosteroids and antihistamines). TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01646203. Twit Text FOAVip A phase 1 study of anti-TGF receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors ????Cancer Chemother Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=28280971 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28280971 #FOAvip English Wikipedia <ref>{{Cite pmid|28280971 }}</ref> A phase 1 study of anti-TGF? receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors #MMPMID28280971 Tolcher AW ; Berlin JD ; Cosaert J ; Kauh J ; Chan E ; Piha-Paul SA ; Amaya A ; Tang S ; Driscoll K ; Kimbung R ; Kambhampati SR ; Gueorguieva I ; Hong DS Cancer Chemother Pharmacol 2017[Apr]; 79 (4 ): 673-680 PMID28280971 show ga PURPOSE: LY3022859 is an anti-TGF?RII IgG(1) monoclonal antibody that inhibits receptor-mediated signaling activation. The primary objective of this phase I study was to determine a phase II dose in patients with advanced solid tumors. Secondary objectives were to assess safety and pharmacokinetics (PK). METHODS: LY3022859 was infused intravenously (IV) at 1.25 mg/kg over 1 h every 2 weeks (Q2W) (cohort 1A) and at flat doses of 12.5 mg (cohort 1B) and 25 mg (cohort 2) over 3 h Q2W. RESULTS: Fourteen patients were enrolled in cohorts 1A (n = 2), 1B (n = 5), and 2 (n = 7). DLTs were experienced by both patients in cohort 1A (infusion-related reaction) and 2 patients in cohort 2 (cytokine release syndrome and infusion-related reaction). No MTD was determined. At the 25 mg dose level (cohort 2), after fifth infusion, LY3022859 had a short t(1/2) (4.37-7.80 h) and rapid clearance (CL(ss), 0.412 L/h). Exposure increased twofold (from 28.5 to 60.2 ?g·h/mL) with increase in dose from 12.5 to 25 mg. No accumulation was observed after repeat administration. CONCLUSIONS: The MTD for LY3022859 was not determined. Dose escalation beyond 25 mg was considered unsafe due to worsening symptoms (uncontrolled cytokine release) despite prophylaxis (corticosteroids and antihistamines). TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01646203. |Adult [MESH] |Aged [MESH] |Antibodies, Monoclonal/adverse effects/pharmacokinetics/*therapeutic use [MESH] |Antineoplastic Agents/adverse effects/pharmacokinetics/*therapeutic use [MESH] |Cohort Studies [MESH] |Cytokines/metabolism [MESH] |Dose-Response Relationship, Drug [MESH] |Female [MESH] |Half-Life [MESH] |Humans [MESH] |Infusions, Intravenous [MESH] |Male [MESH] |Maximum Tolerated Dose [MESH] |Middle Aged [MESH] |Neoplasms/*drug therapy [MESH] |Receptors, Transforming Growth Factor beta/*antagonists & inhibitors [MESH] |Treatment Outcome [MESH]A phase 1 study of anti-TGF? receptor type-II monoclonal antibody LY30(epmc).pdf DeepDyve Pubget Overpricing